76.48
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$70.16
Aprire:
$72
Volume 24 ore:
2.20M
Relative Volume:
1.21
Capitalizzazione di mercato:
$14.80B
Reddito:
$4.41B
Utile/perdita netta:
$21.27M
Rapporto P/E:
239.01
EPS:
0.32
Flusso di cassa netto:
$288.81M
1 W Prestazione:
+10.68%
1M Prestazione:
+11.54%
6M Prestazione:
+3.44%
1 anno Prestazione:
+11.18%
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Confronta INCY con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
INCY
Incyte Corp
|
76.46 | 13.59B | 4.41B | 21.27M | 288.81M | 0.32 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
467.58 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.24 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
326.76 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
596.29 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
305.38 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
2024-12-17 | Iniziato | UBS | Neutral |
2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
2024-10-01 | Iniziato | Wolfe Research | Outperform |
2024-09-18 | Downgrade | Truist | Buy → Hold |
2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
2024-05-23 | Iniziato | Deutsche Bank | Hold |
2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
2024-02-23 | Iniziato | Jefferies | Buy |
2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
2023-11-21 | Downgrade | Goldman | Buy → Neutral |
2023-07-25 | Iniziato | Citigroup | Buy |
2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
2023-01-31 | Iniziato | Piper Sandler | Overweight |
2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
2021-01-07 | Iniziato | Truist | Buy |
2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
2020-06-16 | Iniziato | The Benchmark Company | Hold |
2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2020-03-24 | Ripresa | William Blair | Outperform |
2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
2020-02-04 | Ripresa | BofA/Merrill | Neutral |
2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
2019-10-03 | Iniziato | Mizuho | Buy |
2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
2019-05-21 | Iniziato | Credit Suisse | Neutral |
2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
2019-04-11 | Iniziato | Stifel | Hold |
2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand - Benzinga
Incyte earnings beat by $0.17, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Incyte Q2 2025 reveals revenue miss, stock gains - Investing.com
Incyte lifts annual sales forecast for blood cancer drug after solid quarter - 1470 & 100.3 WMBD
Incyte Q2 Results Top Estimates - Nasdaq
Incyte Q2 2025 slides: revenue up 16%, raises guidance on strong product performance - Investing.com
Incyte Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Incyte misses Q2 earnings estimates, raises Jakafi guidance By Investing.com - Investing.com Canada
Incyte: Q2 Earnings Snapshot - San Antonio Express-News
Incyte Corp Q2 2025 Earnings: EPS of $2.04 and Revenue of $1.216 Billion Surpass Estimates - GuruFocus
Incyte Reports 2025 Second Quarter Financial Results - TradingView
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs - Business Wire
Incyte (INCY) Anticipates Q2 Earnings with Positive Expectations - GuruFocus
How volatile is Incyte Corporation stock compared to the marketRealize exceptional returns through smart trading - jammulinksnews.com
Does Incyte Corporation stock perform well during market downturnsNavigate market shifts with confidence - jammulinksnews.com
Earnings Preview: Incyte to Report Financial Results Pre-market on July 29 - 富途牛牛
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects - MSN
Incyte to present initial data on cancer therapies at ESMO Congress - Investing.com
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025 - Business Wire
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards? - Nasdaq
What analysts say about Incyte Corporation stockFree Buy/Sell Signal Notifications - Autocar Professional
What drives Incyte Corporation stock priceHigh-impact stock picks - jammulinksnews.com
Incyte (INCY) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Is Incyte Corporation a good long term investmentTremendous return rates - jammulinksnews.com
Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Incyte EVP Flannelly sells $83k in shares - Investing.com
Incyte EVP Flannelly sells $83k in shares By Investing.com - Investing.com UK
Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp - MSN
Incyte Announces Q2 2025 Financial Results Call and Webcast Details - MyChesCo
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN
Incyte stock price target raised to $62 from $61 at UBS on sales outlook - Investing.com Canada
Sun Pharma Shares Climb 3%, Leqselvi Settlement - Rediff
Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S. - The Hindu
Sun Pharma launches Leqselvi in US after patent settlement with Incyte Corp - Business Standard
India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement - Reuters
Sun Pharma’s baldness drug Leqselvi debuts in US market after patent dispute settled - The Economic Times
Sun Pharma settles litigation with Incyte Corp - theweek.in
Sun Pharma Settles Incyte Corp Litigation - Rediff
India's Sun Pharma launches anti-baldness drug Leqselvi in US - MarketScreener
Incyte discloses new bicyclooctane KRAS inhibitors - BioWorld MedTech
Anal Cancer Market Research Report 2025-2035 with Competitive Profiles of Incyte, BioMimetix, Bristol Myers Squibb, and AstraZeneca - Yahoo Finance
Incyte’s Q2 2025 Earnings: What To Expect - Barchart.com
Incyte to Report Second Quarter Financial Results - Business Wire
William Blair Maintains ‘Hold’ Rating on Incyte Corporation (INCY), Citing Future Revenue Uncertainties - Insider Monkey
Incyte Announces Equity Awards for New CEO Bill Meury with Performance-Based Incentives - MyChesCo
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock? - MSN
Incyte: New CEO Brings A New Possible Outcome (NASDAQ:INCY) - Seeking Alpha
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):